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Abstract
Background: Early administration of antibiotics in sepsis is associated with improved patient outcomes, but safe and generalizable approaches
to de-escalate or discontinue antibiotics after suspected sepsis events are unknown.
Methods: We used a modified Delphi approach to identify safety criteria for an opt-out protocol to guide de-escalation or discontinuation of
antibiotic therapy after 72 hours in non-ICU patients with suspected sepsis. An expert panel with expertise in antimicrobial stewardship and
hospital epidemiology rated 48 unique criteria across 3 electronic survey rating tools. Criteria were rated primarily based on their impact on
patient safety and feasibility for extraction from electronic health record review. The 48 unique criteria were rated by anonymous electronic
survey tools, and the results were fed back to the expert panel participants. Consensus was achieved to either retain or remove each criterion.
Results: After 3 rounds, 22 unique criteria remained as part of the opt-out safety checklist. These criteria included high-risk comorbidities, signs of
severe illness, lack of cultures during sepsis work-up or antibiotic use prior to blood cultures, or ongoing signs and symptoms of infection.
Conclusions: The modified Delphi approach is a useful method to achieve expert-level consensus in the absence of evidence suifficient to
provide validated guidance. The Delphi approach allowed for flexibility in development of an opt-out trial protocol for sepsis antibiotic
de-escalation. The utility of this protocol should be evaluated in a randomized controlled trial.
Keywords: modified Delphi; antimicrobial stewardship; Sepsis; patient safety; protocol development
(Received 24 June 2021; accepted 20 September 2021)

Early administration of antibiotics in sepsis is associated with reduced
mortality.1 The Centers for Medicare and Medicaid Services (CMS)
amended its Core Measures program in 2015 to mandate a
National Quality Forum-endorsed quality measure (SEP-1) that
required early recognition and bundled management of sepsis.2
The all-or-nothing sepsis bundle was based on elements from the
Surviving Sepsis Campaign (SSC), which strengthened recommendations for sepsis management in 2016 to include broad-spectrum antibiotics administration within 1 hour of sepsis recognition.3,4 The strict
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time-oriented approach was criticized for the potential unnecessary or
overly broad administration of antimicrobials among patients who
ultimately did not have a diagnosis of infection or sepsis.5–8 In one
study, ∼40% of patients with suspected sepsis were adjudicated to lack
infection or represent “possible” sepsis.9 Although the SSC guidelines
promote thoughtful, daily assessments for antibiotic de-escalation, it
does not contain a de-escalation or discontinuation measure to avoid
the unintended consequences of excess antibiotics. Standardized
processes to encourage antibiotic de-escalation or discontinuation
(hereafter assumed to be a subset of ‘de-escalation’) after suspected
sepsis events need further development.
Antibiotic stewardship programs (ASPs) have experience performing antibiotic de-escalation reviews and protocolized interventions. For example, intravenous to oral conversion protocols
performed by clinical pharmacists utilize standard eligibility criteria and provide a recommendation, while allowing the treating
physician to decline the recommendation if appropriate.10–13
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Antibiotic decision making is a highly nuanced thought process,
requiring assessment and reassessment of multiple patient-specific
clinical factors. Safety becomes a key focus when engaging clinicians in such complex decisions. Protocols that allow clinicians
to “opt-out” of a process (ie, clinicians retain autonomy to accept
for forego the ‘intervention’) provide a distinct advantage in gaining acceptance, especially when objective data elements in the
medical record may not fully capture an individual clinical scenario. Opt-out protocols have been successfully used to improve
HIV screening, to decrease unnecessary use of proton pump inhibitors, to avoid adverse outcomes among ventilated patients, and to
prevent catheter-related infections.14–17 Patients started on broadspectrum antibiotics because sepsis was initially suspected may
benefit from an opt-out intervention to trigger antibiotic
de-escalation or discontinuation.
In this study, we aimed to achieve consensus among members
of an expert panel in defining objective high-risk exclusion
(‘safety’) criteria, feasibly obtained during chart review, to identify
patients unlikely to benefit from ongoing broad-spectrum antibiotics 72 hours after a suspected sepsis event. These criteria would
then be used to develop an opt-out trial protocol to engage clinicians in discussion of antibiotic de-escalation for low-risk patients
with suspected sepsis.
Methods
We performed a modified Delphi, expert-consensus-building
process to identify safety criteria for an opt-out protocol to guide
de-escalation of antibiotic therapy among qualifying non-ICU
adult patients with suspected sepsis. The modified-Delphi process
included convening the expert panel, literature review and compilation of a list of candidate criteria, and 3 rounds of iterative
discussion and electronic surveys to rate and then refine candidate
criteria for the protocol.18 Expert panel discussions were held via
web-based teleconferences. Participants completed 3 electronic
surveys during calendar year 2017. The study was deemed exempt
from review by the institutional review board.
Convening the expert panel
Expert panelists were voluntary participants identified by the study
team and CDC partners across multiple institutions in the United
States by their experience in critical care, antimicrobial stewardship, infection prevention, and interests in sepsis care and research.
Invited panelists were from prospective trial sites, which included
5 tertiary-care hospitals in the CDC Prevention Epicenters
Program and 3 community hospital partners, in addition to
CDC experts. Panelists were selected to produce a range of experience in both academic and community hospital settings,
including pharmacists and physicians. The panel was moderated through the modified Delphi process by an expert in behavioral science (R.L.S.).
Literature review and compilation of candidate safety
criteria
The literature review to identify candidate safety criteria included
a PubMed search of articles from the preceding 20 years using the
the terms ‘sepsis’ and ‘septicemia.’ Articles were further narrowed
to identify observational and experimental studies that focused
on treatment of sepsis. The study team reviewed candidate
articles with the expert panel for additional recommended studies. Candidate criteria from the following publication types were
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considered: (1) inclusion and exclusion criteria in sepsis treatment trials, (2) criteria used for antibiotic de-escalation and discontinuation in prospective trials of sepsis therapies, and (3)
objective criteria used to define clinical response for patients presenting with sepsis in interventional and observational studies.
The candidate criteria were reviewed internally by investigators
and were categorized into 6 groups: study inclusion criteria, antibiotic exposures, comorbidities, laboratory data, signs and symptoms of infection, and severity of illness. The parameters were
presented to the expert panel across 3 rounds with anonymous,
electronic surveys. The expert panel was given the opportunity to
add to the list of candidate parameters with each discussion.

Electronic survey development
The list of parameters was compiled into electronic survey rating
tools using Qualtrics survey software (Seattle, WA). The first electronic survey presented panelists with all criteria from the literature review. Panelists were asked to assign each criterion as
“retain” (keep as is or modify) or “remove” (no longer consider
for the protocol) according to their belief that the criterion would
assist in identifying patients eligible for antibiotic de-escalation.
Parameters with consensus (>66.6% agreement on either “retain”
or “remove”) were presented during panel discussion for confirmation of results. Discussions then focused on addressing and voicing
the rationales of panel members regarding ratings on criteria that
did not achieve consensus. Parameters that were retained, modified, or did not achieve consensus continued to the next round.
The second and third electronic surveys used a standardized
case-scenario format to present each criterion in clinical context.
In the second survey, panelists were asked to answer a yes-or-no
question in response to each clinical vignette that showed resolution of sepsis symptoms plus the criterion to be judged: “Should
antibiotics be stopped in the patient on day 3 after suspected
sepsis?” Because panelists had the opportunity in the first round
to discuss rationales for criteria that did not achieve consensus,
the minimum required concordance for retention or removal of
criteria in round 2 was increased to 80%. Criteria that were below
90% but above 80% concordant were discussed with the expert
panel for clarification and/or modification. Criteria that scored
≥90% agreement to stop antibiotics were removed from the pool
without further discussion.
The third electronic survey asked panelists to assess each criterion for feasibility and safety. Panelists were asked to review a
case scenario and rate their agreement on a 7-point Likert scale
for 2 declarative statements: “Stopping antibiotics on day 3 is safe”
and “Determining this patient has (criterion) is feasible” (Fig. 1).
Ratings were dichotomized into binary outcomes, and percent
concordance for agree (‘somewhat agree’ through ‘strongly agree’)
or disagree (‘strongly disagree’ through ‘neither’) were evaluated.
Each criterion was evaluated for removal during panel discussion
if the panel rated with >80% concordance that discontinuing antibiotics was safe or <80% concordance that the criteria could be feasibly identified by chart review. Criteria retained through 3 rounds
and discussions were considered the final consensus criteria. Final
criteria were included in a draft of the opt-out protocol safetycheck screening criteria and were presented for review by the
expert panel during the last panel meeting. Feedback, comments,
and final suggestions were incorporated into the De-escalating
Empiric Therapy: Opting Out of Rx for Suspected Sepsis, or
“DETOURS,” trial protocol.
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Fig. 1. Case-scenario and safety and feasibility declarative statements example. Note. Each criterion was discussed during round 3 due to the survey results indicating <80%
agreement in the feasibility of this parameter being identified by chart review. The expert panel agreed to modify and combine criteria to exclude patients with new chest radiograph infiltrate with or without purulent sputum.

Results
The expert panel included 23 members across 4 CDC Prevention
Epicenters and 8 healthcare institutions. All members were
retained through the conclusion of the Delphi process. Each survey
had at least 17 respondents, and panel discussions included at least
11 members. Community hospitals, academic centers and CDC
members were represented during each discussion. The literature
review yielded 34 articles from which an initial list of 75 candidate
criteria were reviewed (Supplementary Table 1). The candidate
criteria were deduplicated to 48 unique criteria grouped into
6 categories: inclusion criteria, antibiotics, comorbidities, laboratory data, signs and symptoms, and disease severity (Fig. 2 and
Supplementary Table 2). The 4 criteria identified as eligibility
requirements for the proposed protocol were not included in
the expert panel Delphi process: patient not located in intensive
care unit, patient located on an adult medical or surgical unit,
antibiotics initiated for suspected sepsis, and patient remained
on any broad-spectrum antibiotics at 72 hours after the sepsis event.
Round 1
The remaining 44 parameters were included in the first electronic
survey in which panelists rated to retain or remove each criterion.
Also, 14 parameters (32%) had a high degree of concordance
(>66% of respondents) to either retain or remove. The expert panel
discussion focused primarily on the criteria with a remove consensus; criteria with retain concordance would move on to round 2. Of
the 10 criteria discussed, 6 were confirmed for removal and 4
parameters were retained. Criteria that the expert panel readily
agreed to remove from consideration for the opt-out protocol
in round 1 related primarily to patient demographics or comorbidities. For example, the criteria “patients from a nursing
home” or “patients with a hospitalization in the prior 90 days”
were deemed too restrictive and would limit eligibility for
patients that would otherwise benefit from antibiotic de-escalation.
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In contrast, criteria related to specific clinical scenarios produced
varied responses among panel members. For example, the panel
debated over the criterion “exclude if leukocytosis is present (white
blood cell count > 11,000 per mm3).” Optimal parameters for a
white blood cell count threshold, or whether recent white blood
cell values should be considered, were less clear. The panel retained
the leukocytosis criterion with modification for subsequent
rounds. During round 1, the panel recommended the addition
of 2 criteria for review in subsequent rounds: “exclude if antibiotics
administered prior to blood culture” and “exclude if patient is on
perioperative prophylaxis.”
Round 2
In total, 40 parameters were presented via the round 2 survey in
case-based scenarios. The panel was >90% concordant on the decision to stop antibiotics in 12 case scenarios, and these criteria were
removed from the pool after brief review. Further discussion with
the expert panel involved 4 criteria that were near concordance
(80%–90%) in antibiotic decision making: “patient has bronchiectasis,” “patient has asplenia,” “patient is pregnant,” and “patient is
expected to die within 48 hours.” The first 3 criteria were retained
to rate safety and feasibility in round 3, and the last was removed.
The panel estimated cases with impending mortality to have no
significant safety concern if the clinician retained the ability to
opt out. To further simplify the remaining pool, the panel discussed criteria that were similar and could be combined. For example, “patients on high-dose, long-term corticosteroids” was
incorporated into “patients on immunosuppressive agents.”
Round 3
The third survey included 26 criteria to evaluate feasibility and
safety. In total, the expert panel discussed 5 parameters that scored
<80% for feasibility or >80% for safety of stopping antibiotics. All
criteria were retained; however, the panel further simplified criteria
to increase feasibility for chart extraction. For example, 3 criteria
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Fig. 2. DETOURS panel criteria decisions flow diagram. (a) Round 1 had 19 survey responses and 13 panel members present for discussion. (b) Round 2 had 17 survey responses
and 14 panel members present for discussion. (c) Round 3 had 17 survey responses and 11 panel members present for discussion. Note. Sankey diagram demonstrates criteria
discussion, removal, and addition during each round of the Modified Delphi process. Detailed information on specific criteria is provided in Supplementary Table 1. DETOURS,
De-escalating Empiric Therapy: Opting Out of Rx for Suspected Sepsis.

that related to chest radiograph infiltrates plus additional findings
were encompassed into the single parameter of “new chest x-ray
infiltrate.” The remaining 22 criteria were placed into a draft for
the opt-out protocol safety checklist. The protocol was reviewed
with the expert panel with a mock-up graphic to obtain final
comments (Fig. 3).
Discussion
The primary finding of this protocol development program was
that a multidisciplinary panel of experts in antimicrobial stewardship, critical care, and infectious diseases can achieve consensus through a modified Delphi approach to identify safety
criteria for an opt-out protocol for antibiotic de-escalation in
patients with suspected sepsis. Although previous studies have
used a modified Delphi approach to identify hospital ASP structure
and ASP metrics, to our knowledge, this is the first use of a modified
Delphi approach to inform development of a randomized, controlled
study trial protocol in antimicrobial stewardship.19,20
The Delphi approach is an important tool in the setting
of incomplete knowledge, as it can synthesize the cumulative
experience of an array of subject-matter experts. Antimicrobial
de-escalation, although broadly recommended as a strategy in
clinical guidelines, has limited evidence for safety in patients with
sepsis, including few randomized controlled trials, and thus relies
heavily on subject matter expertise.21–23 The modified Delphi
approach allowed multiple participants with diverse expertise to
discuss complex patient-care scenarios and achieve consensus
on a set of safety criteria. The case-based format and anonymous
survey rating tools were effective at highlighting different
approaches to patient care among the DETOURS panel that result
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from a lack of standardized guidelines. At completion of the Delphi
process, the DETOURS panel understood and agreed with the
rationale behind each criterion in the final opt-out protocol.
Furthermore, the panel process promoted familiarity with the
study protocol among stakeholders at institutions intended to be
part of the randomized, controlled trial.
The DETOURS panel discussed 2 key factors when reviewing
criteria for antibiotic de-escalation: patient safety and feasibility.
Discussions of each criterion focused primarily on patient safety
as well as identifying scenarios where benefit would be gained
by review for de-escalation. The proposed intervention required
clinician engagement in evaluating patients for antibiotic discontinuation or de-escalation. Panel members were inclined to identify
criteria that would promote safe recommendations from the local
stewardship team and were feasible for electronic chart abstraction. Any criteria that required detailed, bedside knowledge of
the patient were deemed impractical. Detailed criteria that
remained at the end of the Delphi process are provided in the
Supplementary Material.
Development of an opt-out protocol, in which clinicians reserve
final decision-making power, allow greater flexibility in interpretation of each criterion or clinical scenario because the opt-out
mechanism maintains clinician autonomy as a back-stop for safety.
For example, the ‘Wake Up and Breath Collaborative’ demonstrated the utility and safety of an opt-out protocol for evaluating
the appropriateness of spontaneous breathing trials (SBTs) and
spontaneous awakening trails (SATs) in ventilated patients on a
daily basis. The increased monitoring was associated with lower
rates of ventilator-associated events, yet the decision to proceed
safely with SBTs and SATs remained with clinicians.16 Similarly,
the DETOURS panel did not need to achieve perfection in selection
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Fig. 3. Flow chart with proposed criteria for DETOURS randomized, controlled trial. Note. DETOURS: De-escalating Empiric Therapy: Opting Out of Rx for Suspected Sepsis.
Hashed box indicates the Opt-Out criteria sekected through the modified Delphi process.

of the opt-out protocol safety criteria, knowing that clinical judgments could overrule the criteria obtained from chart review. For
example, the criterion to exclude patients with expected mortality
within 48 hours was initially included for evaluation by the panel
due to patient safety concerns. However, end-of-life care also provides opportunities for antibiotic de-escalation.24 In the opt-out
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protocol, clinicians would retain the ability to continue antimicrobials in cases of patient safety or individual patient/family goals.
Thus, the panel removed this exclusion, allowing end-of-life scenarios to be evaluated for de-escalation opportunities.
Our study using the modified Delphi approach had limitations.
First, the expert panel was large and was composed of members
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across multiple centers in the United States; thus, not every
member could participate on every task, and time was limited in
each teleconference discussion. Due to the panel composition, generalizablility outside the United States was also limited. However,
the structure allowed for a diversity of opinions, and all members
did have opportunity to participate in written surveys. Second, the
focus on patient safety may have led to overly narrow criteria and
more “missed opportunities” for de-escalation. Finally, the criteria
evaluated by the expert panel did not capture some specific patient
scenarios (ie, asymptomatic bacteriuria, endocarditis, osteomyelitis, or medical antibiotic prophylaxis) that may or may not appropriately trigger a review for antibiotic de-escalation.
The modified Delphi approach and expert panel review process
led to the development of safety criteria for an opt-out protocol to
guide antibiotic cessation or de-escalation after initiation of antibiotics for suspected sepsis. The efficacy of this protocol as a tool to
improve antibiotic use will require prospective evaluation in a randomized controlled trial.
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